Radiopharm Theranostics Ltd (rad) Logo

Radiopharm Theranostics Ltd (RAD)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

Radiopharm Theranostics

Radiopharm is focused on developing and commercialising a world-class platform of radiopharmaceutical products for both therapeutic and diagnostic applications in precision oncology.

Radiopharm currently has a pipeline of four licenced platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development, from some of the world’s leading universities and institutes.

Key Details
Established
2021
Treatments
4
Industry
Cancer Treatment
Primary Market
Radiopharmaceuticals
Updated: 01 Nov 2021

Why Invest in RAD

Highly prospective portfolio comprising clinical and pre-clinical stage radiopharmaceutical assets for both diagnostic and therapeutic applications, targeting some of the largest markets in cancer

Five Phase 1 clinical trials completed, five Phase 2 clinical trials ongoing and two Phase 1 clinical trials ongoing

World-class management team comprising C-suite executive team recruited from the most prestigious radiopharmaceutical companies and universities globally

Four novel clinical platforms spanning all size molecules and antibodies. 133 patients have been dosed across the portfolio to date

People

Management

Paul Hopper

Executive Chairman

Paul is the Founder of Radiopharm Theranostics. He has over 25 years experience in the biotech, healthcare & life sciences sectors.

Profile

Paul Hopper

Executive Chairman

Paul is the Founder of Radiopharm Theranostics. He has over 25 years experience in the biotech, healthcare & life sciences sectors.

Focussed on start-up and rapid growth companies, he has served as either Founder, Chairman, non-executive director, or CEO of more than fifteen companies in the US, Australia and Asia.

Previous and current Boards include Imugene, Chimeric Therapeutics, Viralytics, Prescient Therapeutics, Polynoma and Suda Pharmaceuticals. His experience covers extensive fund raising in US, Australia, Asia and Europe, and he has deep experience in corporate governance, risk and strategy. He also has many years experience in providing corporate advice and guidance, financial analysis and management of companies of differing sizes and financial circumstances

Riccardo Canevari

Managing Director and Chief Executive Officer
Nov 2021 - Present

Riccardo has broad and deep experience across specialty pharma, oncology and radiopharmaceuticals.

Profile

Riccardo Canevari

Managing Director and Chief Executive Officer

Nov 2021 - Present

Riccardo has broad and deep experience across specialty pharma, oncology and radiopharmaceuticals.

He was most recently Chief Commercial Officer of Novartis company Advanced Accelerator Applications, one of the leading radiopharmaceutical and nuclear medicine companies globally. He was responsible for global commercial strategy and country organisations in ~20 countries across North America, Europe and Asia. He was lead for Lutathera in-market growth strategy and execution to build a blockbuster asset and lead on the prelaunch plan for Lu-PSMA 617 in metastatic prostate cancer.

He assessed Go To Market Models for each priority country and access to other markets. Prior to this Riccardo was Senior Vice President and Global Head, Breast Cancer Franchise for Novartis Oncology since 2017, overseeing the launch of major breast cancer products including KISQALI and PIQRAY. He has also held various management roles with Novartis Pharma and Ethicon/Johnson&Johnson.

Professor David Mozley

Chief Medical Officer

David is a Professor of Nuclear Medicine with 30+ years in the nuclear medicine field.

Profile

Professor David Mozley

Chief Medical Officer

David is a Professor of Nuclear Medicine with 30+ years in the nuclear medicine field.

He was most recently at Cornell University where he was Chief of Nuclear Medicine and single-site Principal Investigator for first-in-human pharmaceutical industry contracts from three different companies using novel radiopharmaceuticals as major endpoints. He was also the Physician Sponsor of 10 investigational new drug applications. At University Pennsylvania he was PI awarded more than $8M in NIH RO1 grants relating to radiopharmaceutical development. He has participated in over 60 clinical trials at Eli Lily and over 100 trials at Merck in novel radiopharmaceutical development.

Previously he was at Endocyte as Vice President of Imaging, coordinating efforts to take imaging based theranostics to market. He has co-authored more than 100 peer-reviewed publications mostly focused on radiopharmaceutical development and is widely renowned as a Board Certified physician.

Dr Thom Tulip

Chief Technology Officer

Thom has spent more than 25 years in the development and commercialisation of radiopharmaceuticals and imaging agents.

Profile

Dr Thom Tulip

Chief Technology Officer

Thom has spent more than 25 years in the development and commercialisation of radiopharmaceuticals and imaging agents.

He has served in senior leadership roles at Navidea BioPharmaceuticals Inc, Alseres Pharmaceuticals, Lantheus Medical Imaging (LMI), Bristol Myers Squibb (BMS) and DuPont. He was a Board Member of the Academy of Molecular Imaging and Chairperson of its Institute for Molecular Technologies.

Dr Tulip was Chairperson of the Society of Nuclear Medicine Corporate Advisory Board and served as a Director of the Council of Radionuclides and Radiopharmaceuticals. He serves on the Board of Directors of the Medical Imaging Technology

Phillip Hains

Chief Financial Officer

Phillip is a Chartered Accountant operating a specialist public practice, ‘The CFO Solution’.

Profile

Phillip Hains

Chief Financial Officer

Phillip is a Chartered Accountant operating a specialist public practice, ‘The CFO Solution’.

The CFO Solution focuses on providing back office support, financial reporting and compliance systems for listed public companies (particularly biotechnology companies).

Phillip has over 25 years experience in providing businesses with accounting administration, compliance and general management services.

Alison Gartner

Project Manager

Alison has over 20 years experience as a biotech analyst and life science investor across ASX listed and private companies through her investment management roles at Asia Union Investments and life science fund BioScience Managers.

Profile

Alison Gartner

Project Manager

Alison has over 20 years experience as a biotech analyst and life science investor across ASX listed and private companies through her investment management roles at Asia Union Investments and life science fund BioScience Managers.

She is experienced in the establishment of VC and life science funds, and the portfolio management of assets from private start-ups through to FDA approvals, including involvement in private and public ASX capital raisings.

Ms Gartner is a Director of the National Foundation of Medical Research and Innovation, Project Manager at Chimeric Therapeutics and co-founder of Evidentli Pty Ltd.

Board of Directors

Paul Hopper

Executive Chairman

Paul is the Founder of Radiopharm Theranostics. He has over 25 years experience in the biotech, healthcare & life sciences sectors.

Profile

Paul Hopper

Executive Chairman

Paul is the Founder of Radiopharm Theranostics. He has over 25 years experience in the biotech, healthcare & life sciences sectors.

Focussed on start-up and rapid growth companies, he has served as either Founder, Chairman, non-executive director, or CEO of more than fifteen companies in the US, Australia and Asia.

Previous and current Boards include Imugene, Chimeric Therapeutics, Viralytics, Prescient Therapeutics, Polynoma and Suda Pharmaceuticals. His experience covers extensive fund raising in US, Australia, Asia and Europe, and he has deep experience in corporate governance, risk and strategy. He also has many years experience in providing corporate advice and guidance, financial analysis and management of companies of differing sizes and financial circumstances

Riccardo Canevari

Managing Director and Chief Executive Officer
Nov 2021 - Present

Riccardo has broad and deep experience across specialty pharma, oncology and radiopharmaceuticals.

Profile

Riccardo Canevari

Managing Director and Chief Executive Officer

Nov 2021 - Present

Riccardo has broad and deep experience across specialty pharma, oncology and radiopharmaceuticals.

He was most recently Chief Commercial Officer of Novartis company Advanced Accelerator Applications, one of the leading radiopharmaceutical and nuclear medicine companies globally. He was responsible for global commercial strategy and country organisations in ~20 countries across North America, Europe and Asia. He was lead for Lutathera in-market growth strategy and execution to build a blockbuster asset and lead on the prelaunch plan for Lu-PSMA 617 in metastatic prostate cancer.

He assessed Go To Market Models for each priority country and access to other markets. Prior to this Riccardo was Senior Vice President and Global Head, Breast Cancer Franchise for Novartis Oncology since 2017, overseeing the launch of major breast cancer products including KISQALI and PIQRAY. He has also held various management roles with Novartis Pharma and Ethicon/Johnson&Johnson.

Ian Turner

Non-Executive Director

Ian is a highly experienced radiopharmaceutical and nuclear medicine supply and manufacturing expert with a distinguished C-level career across some of the leading corporations in the sector including CEO and President of Siemens PETNET Solutions from 2010-2012

Profile

Ian Turner

Non-Executive Director

Ian is a highly experienced radiopharmaceutical and nuclear medicine supply and manufacturing expert with a distinguished C-level career across some of the leading corporations in the sector including CEO and President of Siemens PETNET Solutions from 2010-2012.

Prior to that role he was General Manager of ANSTO Radiopharmaceuticals in Sydney Australia, Australia's leading manufacturer of radioisotopes for the nuclear medicine sector. He was also Executive Director of PETNET Australia Pty Ltd. He spent a decade in various C-level roles at Varian Inc in Palo Alto and Melbourne.

Ian was also previously a Director of Coqui Pharmaceuticals until 2019, a company involved in the supply of radioisotopes in the US.

Dr Michael Baker

Non-Executive Director

Michael is currently CEO and MD of ASX listed Suda Pharmaceuticals which is developing technologies in the cell therapy and drug delivery fields.

Profile

Dr Michael Baker

Non-Executive Director

Michael is currently CEO and MD of ASX listed Suda Pharmaceuticals which is developing technologies in the cell therapy and drug delivery fields.

Prior to Suda he was an Investment Manager with Australian life science fund, Bioscience Managers and a senior manager at Hexima Limited. He has a PhD in Biochemistry and was awarded the prestigious Nancy Millis award for the most outstanding thesis for the Faculty of Science, Technology and Engineering in 2010.

He was an Alexander von Humbolt Research Fellow at the University of Cologne. He has an MBA from Melbourne Business School.

Phillip Hains

Chief Financial Officer

Phillip is a Chartered Accountant operating a specialist public practice, ‘The CFO Solution’.

Profile

Phillip Hains

Chief Financial Officer

Phillip is a Chartered Accountant operating a specialist public practice, ‘The CFO Solution’.

The CFO Solution focuses on providing back office support, financial reporting and compliance systems for listed public companies (particularly biotechnology companies).

Phillip has over 25 years experience in providing businesses with accounting administration, compliance and general management services.

Treatments

Treatment

Nano-mAbs

Nano-mAbs is a novel radiopharmaceutical platform invented by Dr Hong Hoi Ting. Nano-mAbs are made using genetically engineered camelid derived single domain antibodies (sdAb) that can be labelled with radioisotopes in order to diagnose and treat specific cancers expressing HER-2, TROP-2, PD-L1 and PTK7 receptors. 

Phase 1 imaging 19 in 33 patients (Shanghai and Germany) is complete, with results indicating the potential for use as whole-body assessment and treatment of HER-2+ cancers with different medical radioisotopes. Therapeutic compassionate use study in HER-2+ breast cancer patients is anticipated to commence in 2HCY2021.

Learn More
Treatment

Pivalate

Pivalate is an 18F-FPIA radiotracer and is the invention of Professor Eric Aboagye of Imperial College London. The technology is based on a short chain carbohydrate which utilises the early steps of fatty acid oxidation and is very stable. In comparison to the clinical standard in PET imaging, 18F-FDG in prostate and brain cancers, Pivalate showed superior imaging performance and was equally good for two breast cancer models. 

Phase 1 diagnostic trial in high- and low-grade glioma is complete. Phase 2 diagnostic renal, glioma and other solid tumours are also recruiting or underway.

Learn More
Treatment

AVβ6 Integrin

AVβ6 is the invention of internationally regarded integrin expert Professor Johannes Notni, formerly at the Technical University of Munich and now Professor at Essen University. AVβ6 is a strong selective ligand for a cell surface protein called αvβ6- integrin. As such, it can accumulate in tissue areas characterised by high αvβ6-integrin levels.

There is compelling evidence that αvβ6-integrin is over expressed in many of the most challenging cancers such as pancreatic, cervical, head & neck and certain lung cancers. 

AVβ6 offers noteworthy performance for radiolabelling with 68Ga and is a promising candidate for early detection of the above-mentioned conditions by PET imaging. A diagnostic compassionate use study in ongoing in Germany in pancreatic and head & neck cancer with ten patients to date.

Learn More
Treatment

PSA-mAb

PSA-mAb is the invention of Professor David Ulmert of UCLA and Essen University. PSAmAb is a humanised monoclonal antibody, capable of targeting free human prostate kallikrien (or prostate specific antigen (PSA)) in prostate cancer cells. The antibody platform enables a theranostic approach for prostate cancer. 

Attachment to 225Ac results in curative treatment by sustained tumour regression and a significant increase in median survival time. PSA-mAb is at pre-clinical stage.

Learn More

Key Milestones

Historical Milestones

Five Phase Two and two Phase One trials underway
133 patients dosed to date
Five Phase One trials complete

Future Milestones

Progress and complete clinical trials
Complete ASX Listing
Obtain regulatory approvals

Investment

Investors

Paul Hopper

BACKGROUND

Executive Chairman of Radiopharm

NanoMab Technology Limited

BACKGROUND

Licensor of Nano-mAbs technology

Capital Raises

ASX Listing
|Nov 2021

The funds raised by this Offer will provide Radiopharm with working capital to support its growth strategy, and will fund payments under the Company’s Licence Agreements, complete drug manufacturing and initiate and progress Phase 1 & Phase 2 clinical trials.

Raised $50m
Offer Price $0.60
Notes

Documents

Prospectus

14 Oct 2021 | Prospectus
PDF (5139.5 KB)

Raise Media Release

17 Aug 2021 | Media Release
PDF (246.9 KB)

Radiopharm Theranostics’ Research Article

30 Jul 2021 | Article
PDF (626.2 KB)

Add RAD to your Watchlist